img
Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study     
Yazarlar
Elif Ertan Baydemir
Türkiye
Neriman Efe Çalışkan
Türkiye
Dr. Öğr. Üyesi Mehmet Cem SABANER Dr. Öğr. Üyesi Mehmet Cem SABANER
Türkiye
Mustafa Doğan
Afyonkarahisar Sağlık Bilimleri Üniversitesi, Türkiye
Özet
The study aimed to evaluate the functional and anatomical results of patients treated with intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (n-AMD) but switched to intravitreal aflibercept (IVA) treatment due to insufficient response treatment. At least six doses of n-AMD were administered IVR to 33 patients who were switched to IVA treatment due to insufficient response and were included in the study. The patients were evaluated at the beginning of the IVR treatment during the transition to IVA treatment and at 6, 12, 18, 24, 30, 36, and 42 months of IVA treatment. After an average of 10.1 ± 5.04 IVR injections, the patients who were accepted as insufficient response were treated with IVA. The central macular thickness of the patients was evaluated at the beginning of the treatment, immediately before, and after the initiation of IVA treatment at 6, 12, 18, 24, 30, 36, 42 months. It was as follows: 325.21 ± 123.04, 351.42 ± 126.09, 284.81 ± 112.65, 296.68 ± 89.17, 282.61 ± 81.58, 292.27 ± 109, 92,269.75 ± 97.14, 267.50 ± 87.56, and 266.82 ± 88.35 μm. According to the best-corrected visual acuity (BCVA), it was initially 0.89 ± 0.65; 1.08 ± 0.53 during the transition to IVA; 0.91 ± 0.46 6 months after IVA; 12 1.14 ± 0.59; 0.94 ± 0.55 at 18; 1.07 ± 0.49 at 24; 1.15 ± 0.57 at 30; 1.06 ± 0.45 at 36, and 1.13 ± 0.46 LogMAR ( Logarithm of the Minimum Angle of Resolution) at the 42 month. In conclusion, in n-AMD patients with inadequate response to intravitreal ranibizumab or with relapse, and therefore, switched to aflibercept treatment, the anatomical improvement and sustainment were observed, however, functional recovery could not be achieved.
Anahtar Kelimeler
Aflibercept | age-related macular degeneration | ranibizumab | switch
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı NIGERIAN JOURNAL OF CLINICAL PRACTICE
Dergi ISSN 1119-3077
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q4
Makale Dili İngilizce
Basım Tarihi 12-2021
Cilt No 24
Sayı 12
Sayfalar 1824 / 1827
Doi Numarası 10.4103/njcp.njcp_696_20
Makale Linki http://dx.doi.org/10.4103/njcp.njcp_696_20